Verve Therapeutics, Inc.
http://www.vervetx.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Verve Therapeutics, Inc.
Audience Unimpressed By Verve’s Base Playing
Verve’s shares dropped hard on its recent Phase I data, and it might be up to Lilly to retore investor confidence.
Verve’s Cholesterol Gene Editing Hits Milestone – With Lilly Now Onboard
The gene-editing company has achieved proof-of-concept for its base-editing platform in three patients – but safety concerns have sent its share price into decline.
Deal Watch: Lilly Will Take Over Beam’s Rights To Verve Cardiovascular Assets
Lilly looks To Elektrofi for help on subcutaneous injectable therapies, while NAYA will merge with INVO and acquire two antibodies from Cytovia. Plus deals involving Hummingbird/Endeavor, Basilea/Gravitas/Intron, Lilly/Mablink and Sotio/Synaffix.
Gene Therapy: What To Expect Now And In The Future
The US FDA could approve as many new gene therapies in 2023 as it has in the previous five years. Development in the field has rapidly accelerated, but still faces hurdles.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Nanotechnology, Chips, etc.
-
Drug Discovery Tools
- Genomics-Proteomics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice